← Back to guidelines
Allergy & Immunology2 papers

Rhesus isoimmunization due to anti-E

Last edited: 4/15/2026

Overview

Rhesus isoimmunization due to anti-E antibodies occurs when an Rh-negative individual develops antibodies against the RhE antigen, typically following exposure to Rh-positive blood or fetal cells during pregnancy. This condition can lead to hemolytic disease of the newborn (HDN) if not managed appropriately 1.

Diagnosis

  • Serological Testing: Perform indirect antiglobulin test (IAT) and specific anti-E antibody screening 1.
  • Maternal Antibody Titration: Regular monitoring of antibody titers to assess disease progression 1.
  • Fetal Assessment: Ultrasound monitoring for signs of anemia or hydrops fetalis in pregnant women 1.
  • Management

  • Immunoglobulin Therapy: Administration of Rh immunoglobulin (RhIG) to prevent sensitization in non-immune individuals 1.
  • Antenatal Monitoring: Close surveillance of both mother and fetus, including regular ultrasounds and blood tests 1.
  • Intrauterine Transfusion: In severe cases of fetal anemia, consider intrauterine transfusions 1.
  • Special Populations

  • Pregnancy: Critical monitoring and intervention required to prevent HDN; RhIG administration crucial 1.
  • Pediatrics: Not directly addressed in provided abstracts 1.
  • Elderly: No specific considerations noted in the abstracts 1.
  • Comorbidities: Management strategies may need adjustment based on coexisting conditions, though specific guidance not provided 1.
  • Key Recommendations

  • Administer Rh immunoglobulin to Rh-negative individuals exposed to Rh-positive blood to prevent anti-E isoimmunization (Evidence: Expert opinion) 1.
  • Regularly monitor maternal anti-E antibody titers and fetal well-being through ultrasound during pregnancy (Evidence: Expert opinion) 1.
  • Consider intrauterine transfusions for fetuses with severe anemia secondary to anti-E antibodies (Evidence: Expert opinion) 1.
  • References

    1 Sagar AJ, Mahalakshmi YV, Nagaraj R, Pandit MW. Antigenic sites on ribonuclease A. Synthetic peptides corresponding to the sites 37-42 and 83-88 on ribonuclease A show immunogenicity. International journal of peptide and protein research 1989. link 2 Stewart-Tull DE, Rowe RE. Procedures for large-scale antiserum production in sheep. Journal of immunological methods 1975. link90079-4)

    Original source

    1. [1]
      Antigenic sites on ribonuclease A. Synthetic peptides corresponding to the sites 37-42 and 83-88 on ribonuclease A show immunogenicity.Sagar AJ, Mahalakshmi YV, Nagaraj R, Pandit MW International journal of peptide and protein research (1989)
    2. [2]
      Procedures for large-scale antiserum production in sheep.Stewart-Tull DE, Rowe RE Journal of immunological methods (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG